Back
Grace Therapeutics, Inc. Stock Predictions
Valuation Up 5,000%. Shares Now $0.85 - Still Early?
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Buy
51
GRCE
Grace Therapeutics, Inc.
Last Price:
$3.36
Seasonality Move:
-16.02%
7 Day Trial
ALL ACCESS PASS
$
7
14K Investors Got In Earlier. You Still Can.
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiGrace Therapeutics, Inc. Stock Forecast
-
Is Grace Therapeutics, Inc. Stock Undervalued?The current Grace Therapeutics, Inc. [GRCE] share price is $3.35. The Score for GRCE is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
-
GRCE is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
Will Grace Therapeutics, Inc. Stock Go Up Next Year?
Data Unavailable
Grace Therapeutics, Inc. Stock Rating
Data Unavailable
Grace Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
gracetx.com
52-Week Data
52-Week High:
4.69
52-Week Low:
1.75
Prediction Charts
Market Cap:
51.8M
Price in USD:
3.35
Volume:
58.1K
Beta:
1.36
Technical Analysis
SMA50:
3.15
SMA100:
3.13
SMA200:
2.92
52-Wk Change:
-13.66%
Stock Predictions
-
Is Grace Therapeutics, Inc. stock public?Yes, Grace Therapeutics, Inc. is a publicly traded company.
-
What is the Grace Therapeutics, Inc. stock quote today?The Grace Therapeutics, Inc. stock price is 3.35 USD today.
-
How to buy Grace Therapeutics, Inc. stock online?You can buy Grace Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-28 | 3.22 | 3.18 | 3.22 | 3.16 |
| Dec-1 | 3.17 | 3.17 | 3.20 | 3.13 |
| Dec-2 | 3.15 | 3.14 | 3.17 | 3.08 |
| Dec-3 | 3.12 | 3.16 | 3.21 | 3.10 |
| Dec-4 | 3.19 | 3.28 | 3.28 | 3.14 |
| Dec-5 | 3.26 | 3.22 | 3.28 | 3.22 |
| Dec-8 | 3.22 | 3.35 | 3.35 | 3.21 |
| Dec-9 | 3.39 | 3.47 | 3.54 | 3.39 |
| Dec-10 | 3.48 | 3.39 | 3.48 | 3.36 |
| Dec-11 | 3.35 | 3.36 | 3.46 | 3.35 |
| Dec-12 | 3.30 | 3.31 | 3.40 | 3.30 |
| Dec-15 | 3.30 | 3.24 | 3.42 | 3.24 |
| Dec-16 | 3.24 | 3.34 | 3.40 | 3.24 |
| Dec-17 | 3.40 | 3.35 | 3.48 | 3.35 |
Grace Therapeutics, Inc. Earnings
Data Unavailable
Grace Therapeutics, Inc. Forecast Revenue Growth
Data Unavailable
-
Analysts estimate an earnings increase this quarter of $0.08 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.23 per share, and an increase next year of $0.31 per share.
* Grace Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.